{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IIIb-d+Malignant+Melanoma", "query": { "condition": "Stage IIIb-d Malignant Melanoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-27T01:15:44.016Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03618641", "title": "CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Lymph Node Cancer" ], "interventions": [ { "name": "CMP-001", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2018-08-08", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03618641" }, { "nct_id": "NCT04401995", "title": "Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Vidutolimod (CMP-001)", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "[18F]F-AraG PET/CT", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-09-02", "completion_date": "2024-08-16", "has_results": false, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401995" }, { "nct_id": "NCT03769155", "title": "VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "VX15/2503", "type": "BIOLOGICAL" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-12-13", "completion_date": "2032-12-15", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03769155" }, { "nct_id": "NCT07049276", "title": "The Multicentre Selective Lymphadenectomy Trial - 3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cutaneous Melanoma, Stage III" ], "interventions": [ { "name": "Index lymph node resection", "type": "PROCEDURE" }, { "name": "Therapeutic lymph node dissection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Melanoma Institute Australia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2025-10-01", "completion_date": "2040-08", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07049276" }, { "nct_id": "NCT03567889", "title": "Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma Stage IIIB", "Melanoma Stage IIIC", "Melanoma Stage IIID" ], "interventions": [ { "name": "Daromun", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Adjuvant therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Philogen S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2018-09-20", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 19, "location_summary": "Phoenix, Arizona • La Jolla, California • Orange, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03567889" }, { "nct_id": "NCT04056247", "title": "Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stage IV Non-small Cell Lung Cancer", "Stage IV Malignant Melanoma", "Stage IV Small Cell Lung Cancer", "Stage III Unresectable Non-Small Cell Lung Cancer", "Stage IIIb-d Malignant Melanoma" ], "interventions": [ { "name": "Plasma sample collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "OncoHost Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10000, "start_date": "2019-10-01", "completion_date": "2029-10-01", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04056247" }, { "nct_id": "NCT05176470", "title": "Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Melanoma", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Stage IV Melanoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lifileucel", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Richard Wu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2022-07-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176470" }, { "nct_id": "NCT04221438", "title": "Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma of Unknown Primary", "Metastatic Malignant Neoplasm in Lymph Node", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Fluorothymidine F-18", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-09-22", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 10, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • City of Saint Peters, Missouri + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "City of Saint Peters", "state": "Missouri" }, { "city": "Creve Coeur", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04221438" }, { "nct_id": "NCT04310397", "title": "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Spartalizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2020-01-29", "completion_date": "2023-10-09", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04310397" }, { "nct_id": "NCT03068455", "title": "An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1844, "start_date": "2017-04-11", "completion_date": "2021-02-02", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-06-27T01:15:44.016Z", "location_count": 33, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 25 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03068455" } ] }